本报讯 （记者矫月）近日，由深圳北理莫斯科大学、莫大-北理工-深北莫应用数学联合研究中心主办， 健康160国际有限公司（以下简称"健康160"）等单位协办的"AI+医疗数据引领大健康行业升级"会议在 深圳北理莫斯科大学成功举办。在会议中，健康160首次披露：其AI驱动医院运营升级方案已助力深圳 某医院实现年增收超5000万元。这一数字背后，是医疗数据要素化价值释放的冰山一角。 "医疗大数据作为第五大生产要素的价值释放窗口已经打开。"与会专家表示，在数据要素市场化配置改 革加速背景下，健康160等平台型企业将率先受益。 健康160集团总裁冀冉在主题演讲中系统展示了其独特的盈利模式。公司以医院微信公众号为数字化主 阵地，构建消费医疗、智慧导诊、医生品牌与院长数据驾驶舱四大模块，形成完整的公众号运营升级方 案，推动医院向数据驱动的精准运营转型。 在平台推广上，健康160依托"公众号私域+平台公域"双轮驱动模式，结合5500万用户数据与华为鸿蒙生 态入口，基于AI精准推荐为医院引流优质患者。这一模式不仅解决了医院在医保控费背景下的增收难 题，更开辟了可复制、可推广的数字化实践路径。 更值得关注的是，健康160已研发测 ...

Core Insights - The first on-site transaction of medical data products in Henan Province has been successfully completed, involving a collaboration between KingMed Diagnostics and Antu Bioengineering [2][3] - The data product traded is "KingMed Infection Data (Invasive Fungal) Distribution Statistics," which provides critical insights into the prevalence of invasive fungal infections across different regions and times, aiding in the development of prevention strategies and treatment optimization [2] Group 1: Transaction Details - The transaction marks a significant step in the compliant circulation of medical data within the healthcare sector [3] - The data product integrates detection information of specific fungal infections nationwide, reflecting epidemiological characteristics [2] Group 2: Company Profiles - Antu Bioengineering, founded in 1998 and listed on the Shanghai Stock Exchange in September 2016, is the first domestic company to focus on the research and manufacturing of in vitro diagnostic products [3] - KingMed Diagnostics is a high-tech service enterprise specializing in third-party medical testing and pathology diagnosis, providing leading diagnostic information integration services across various medical institutions in China [3]